IN THIS ISSUE

Legislation & Regulation
John Carroll
The $50 million needed for regional collaborations was not part of the federal government's budget. Not the end of the world, but not good either.
Tomorrow's Medicine
Thomas Morrow, MD
Natalizumab has received FDA approval. But as with all approved treatments, questions remain about efficacy and clinical importance compared to existing therapies.

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report